Clinical trial Recruiting at 1 site Phase1; Phase2 Interventional Ages 18 to 79

Combined upper-airway electrical stimulation with a drug combo for sleep apnea

Official title: Combination Upper-Airway Electrical and Pharmacological Stimulation for Obstructive Sleep Apnea: A Randomized-Controlled Trial.

Run by Brigham and Women's Hospital · NCT07577661 · Data updated 2026-11-12

This study tests whether adding a drug mix called AtoOxy to an existing hypoglossal nerve stimulation device helps people with sleep apnea sleep better.

More Obstructive Sleep Apnea trials

Quick facts

PhasePhase1; Phase2
Study typeInterventional
Ages18 Years to 79 Years
SexAll
Enrollment24 (estimated)
SponsorBrigham and Women's Hospital
Academic / other
Locations1 site (Boston, Massachusetts)
StatusRecruiting
StartedSeptember 1, 2026
Main results expectedSeptember 1, 2028
Study endsSeptember 1, 2028
Registry record updatedSeptember 21, 2026
Trial IDNCT07577661 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults aged 18-79 with diagnosed OSA who either have a hypoglossal nerve stimulation device or are scheduled for implantation, and who can safely suspend HGNS for testing.

Probably not a fit

Patients who do not experience improved airway stability with HGNS or AtoOxy may receive little or no benefit from the combined approach.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a randomized, placebo-controlled crossover trial in adults with obstructive sleep apnea who have a hypoglossal nerve stimulation (HGNS) device or are planned to receive one. Participants receive four treatment conditions in random order: HGNS plus AtoOxy, HGNS with placebo, AtoOxy alone (HGNS off), and placebo (HGNS off). The primary goal is to see if the combined treatment reduces breathing events during sleep more than HGNS alone. The study also explores whether each intervention helps compared with placebo and characterizes tolerability and safety of the therapies. The approach targets both mechanical airway support and pharmacologic modulation of airway muscles and arousal thresholds.

Why it matters

Potential benefit: If successful, patients may experience fewer breathing disturbances during sleep and improved sleep quality.

How similar studies have gone: Prior studies suggest AtoOxy can increase upper airway muscle tone and raise arousal threshold, but their combined effect with HGNS has not been definitively established.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria for Enrolment:

* Ages 18 - 79 years
* Diagnosed OSA
* Implantation of a hypoglossal nerve stimulation device (HGNS, Inspire Medical) or scheduled for implantation (implantation required for randomization)
* Willingness to withhold HGNS while testing therapies (up to 6 weeks with HGNS off \[with/without pharmacotherapy\] to assess benefits of HGNS therapy).

Exclusion Criteria:

* Any uncontrolled medical condition
* Current use of the medications under investigation.
* Issues relating to short-term withdrawal of HGNS therapy

  * Excluded: Occupational driving (truck drivers, fork-lift operation, taxi/uber drivers)
  * Excluded: History of traffic accidents attributable to sleepiness or fatigue (\<2 years).
* Use of SNRIs/SSRIs or anticholinergic medications during the study.
* Conditions likely to affect obstructive sleep apnea physiology: neuromuscular disease or other major neurological disorder, heart failure (also below), or any other unstable major medical condition.
* Respiratory disorders other than sleep disordered breathing:

chronic hypoventilation/hypoxemia (awake SaO2 \< 92% by oximetry) due to chronic obstructive pulmonary disease or other respiratory conditions.

* Other sleep disorders: narcolepsy, parasomnias. Insomnia
* Contraindications for atomoxetine and oxybutynin, including:

  * hypersensitivity to atomoxetine or oxybutynin (angioedema or urticaria)
  * pheochromocytoma
  * use of monoamine oxidase inhibitors
  * diagnosed benign prostatic hypertrophy, urinary retention
  * suspected benign prostatic hypertrophy / urinary retention based on a positive answer to either of the following questions:

    1. "During the last month, when urinating, have you had the sensation of not emptying your bladder completely more often than 1 out of 5 times?"
    2. "During the last month, have you had a weak urinary stream more often than 1 out of 5 times?
  * known untreated narrow angle glaucoma
  * known bipolar disorder, mania, psychosis
  * known history of major depressive disorder (age\<24).
  * known history of attempted suicide or suicidal ideation within one year prior to screening
  * known clinically significant constipation, gastric retention
  * known pre-existing seizure disorders
  * known clinically-significant kidney disorders (eGFR\<60 ml/min/1.73m2)
  * known clinically-significant liver disorders
  * known clinically-significant cardiovascular conditions
  * moderate-to-severe hypertension (SBP\>160 mmHg or DBP\>100 mmHg measured at baseline; average of evening and morning measures)
  * known cardiomyopathy (LVEF\<50%) or heart failure
  * known advanced atherosclerosis
  * recent cerebrovascular events (within 2 years)
  * recent history of cardiac arrhythmias e.g., atrial fibrillation, QT prolongation (within 2 years)
  * other serious cardiac conditions that would raise the consequences of an increase in blood pressure or heart rate
  * myasthenia gravis
  * pregnancy/breast-feeding

Where it's running

  • Brigham and Women's Hospital
    Boston, Massachusetts, United States
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.